Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00218517 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1
A Phase 2 study of Marijuana Abuse, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT00218517 is a Phase 2 study of Marijuana Abuse that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 19 participants, below the 94-participant average among 4 other Marijuana Abuse trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00218517, a Phase 2 study of Marijuana Abuse, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
During the past 15 years, the demand for treatment for marijuana-related problems in the United States has increased nearly twofold. Selegiline is a medication currently used to treat nicotine dependence. The purpose of this study is to evaluate whether selegiline may be useful in treating individuals with marijuana dependence.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Selegiline hydrochloride
Study Locations (1)
Connecticut
- MRU - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2005-03 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00218517
The ClinicalTrials.gov registry entry for NCT00218517 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 94-participant average among 4 other Marijuana Abuse trials with a reported enrollment target (80% lower). The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Marijuana Abuse appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00218517 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00218517 about?
NCT00218517 is a clinical study titled "Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1". During the past 15 years, the demand for treatment for marijuana-related problems in the United States has increased nearly twofold. Selegiline is a medication currently used to treat nicotine dependence. The purpose of this study is to evaluate whether selegiline may be useful in treating individua...
What is the current status of trial NCT00218517?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2005-03. Estimated completion is 2007-07.
What conditions does trial NCT00218517 study?
This clinical trial studies the following conditions: Marijuana Abuse.
What interventions are being tested in trial NCT00218517?
The interventions under investigation include: Placebo (DRUG), Selegiline hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00218517?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00218517 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Marijuana Abuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.